• Über Taylor Wessing
  • Unsere Anwälte
  • Expertise
    • Branchen
        • Technologie-, Medien & Kommunikation
        • Private Wealth
        • Real Estate, Infrastructure & Energy
        • Life Sciences & Healthcare
        • Aerospace & Defence
        • Automobilindustrie & Mobilität
        • Business & Professional Services
        • Chemieindustrie
        • Konsumgüter und Einzelhandel
        • Bank- & Finanzwesen
        • Hotels, Hospitality & Leisure
        • Logistik & Transport
        • Industrieunternehmen
        • Öffentliche Dienste & Bildungsinfrastruktur
    • Rechtsgebiete
        • Künstliche Intelligenz
        • Bank- & Finanzrecht
        • Marken & Werbung
        • Handels- & Vertriebsrecht
        • Kartell-, Vergabe-, Beihilfe- und Außenhandelsrecht
        • Urheber- und Medienrecht
        • Wirtschaftsstrafrecht und Compliance
        • M&A / Gesellschaftsrecht & Kapitalmarktrecht
        • Daten & Cybersicherheit
        • Disputes & Investigations
        • Arbeitsrecht
        • Umwelt, Planung & Regulierung
        • Environmental, Social & Governance (ESG)
        • Intellectual property
        • Informationstechnologie
        • Patents Technology & Life Sciences
        • Private Client
        • Private Equity
        • Projects, Energy & Infrastructure
        • Immobilienrecht
        • Regulation
        • Restrukturierung & Insolvenzrecht
        • Steuerrecht
        • Venture Capital
  • International
    • Europa
        • Standorte
        • Österreich
        • Belgien
        • Tschechische Republik
        • Frankreich
        • Deutschland
        • Ungarn
        • Italy
        • Niederlande
        • Polen
        • Portugal
        • Republik Irland
        • Slowakei
        • Spanien
        • Großbritannien
        • Ukraine
          Groups & regions
        • CEE Turkish Desk
        • French German Group
        • Unsere Büros
    • Naher Osten & Afrika
        • Standorte
        • Naher Osten
        • Vereinigte Arabische Emirate
          Groups
        • Africa Group
        • Israel Group
        • Unsere Büros
    • Amerika
        • Standorte
        • Latein Amerika
        • USA
          Groups
        • Brazil Group
        • Unsere Büros
    • Asien
        • Standorte
        • Asien
        • China
        • Südkorea
          Groups
        • India Group
        • Japan Group
        • Unsere Büros
  • Insights
    • Insights
        • Featured Topics
        • Artificial intelligence
        • Data Centre Expertise
        • EU-Whistleblower-Richtlinie (HinSchG)
        • Lieferkettengesetz
        • Unified Patent Court
          Content hub
        • Global Data Hub
        • Interface: Digitales Tech-Magazin
        • Podcasts
        • Synapse
        • Alle Insights
    • Events
        • In Präsenz
        • Online
        • Alle Events
    • News
        • Media Center
        • Unternehmensmeldungen
        • Deal Meldungen
        • Alle News
  • Karriere
  • DE
    • English
    • 中文(简体)
    • Français
    • Deutsch
  • Home
  • Team
  • Matthew Royle
Matthew Royle, Ph.D.
Matthew Royle, Ph.D.

Matthew Royle, Ph.D.

Partner

  • London UK
  • Dublin Republik Irland
+44 20 7300 4608
vCard
E-Mail Call me
Featured award

Managing Intellectual Property – IP Stars 2024

Patent star

Scroll to featured award

Matthew specialises in patent litigation, opinion work, supplementary protection certificates (SPCs), paediatric extensions and regulatory advice.

Matthew has a strong science background, holding a PhD in molecular immunology, meaning he gets to grips with the scientific facts of a case quickly.

A leading individual in Chambers and is a rising star in litigation, Matthew has particular experience of acting for clients in the pharmaeutical, biotech and life sciences sectors.  He regularly co-ordinates pan-European litigation and has been involved in hearings in Germany, Netherlands, Belgium and Norway.

Expertise

Rechtsgebiete und Gruppen

Patents Technology & Life Sciences
Disputes & Investigations
Regulatorisches Gesundheitsrecht
IP-rechtliche Streitigkeiten
Tech-Streitigkeiten
Regulatorische Beratung im Bereich Life Sciences
Beilegung von Patent- & Know-how-Streitigkeiten

Branchen

Life Sciences & Healthcare
Biotechnologie
Medizinprodukte
Arzneimittel

CV

Since 2015 Partner, Taylor Wessing
2011 - 2015 Senior Associate, Taylor Wessing
2006 - 2011 Associate, Taylor Wessing
2004 - 2006 Trainee solicitor, Taylor Wessing
2007 Diploma in Intellectual Property Law, Bristol University, UK
2006 Admitted to the Bar, England and Wales
2002 PhD, Molecular Immunology, University of Cambridge, UK
1998 Degree, Medical Microbiology, University of Edinburgh, UK

Karriere

Since 2015 Partner, Taylor Wessing
2011 - 2015 Senior Associate, Taylor Wessing
2006 - 2011 Associate, Taylor Wessing
2004 - 2006 Trainee solicitor, Taylor Wessing

Ausbildung

2007 Diploma in Intellectual Property Law, Bristol University, UK
2006 Admitted to the Bar, England and Wales
2002 PhD, Molecular Immunology, University of Cambridge, UK
1998 Degree, Medical Microbiology, University of Edinburgh, UK

Publikationen

EU Guidance on biosimilar MAbs - what took so long?, Scrip Regulatory Affairs, pp 10-12, 17, July 2012
Neurim - EU Advocate General argues that supplementary protection certificates should be allowed for usage patents, Scrip Regulatory Affairs, p 5, 22, May 2012

Mitgliedschaften

Associate member of CIPA

Fremdsprachen

English

Awards

Managing Intellectual Property – IP Stars 2024

Featured

Patent star

Chambers and Partners UK 2023

Life Sciences (IP/patent litigation) - Band 2: Matthew Royle frequently represents pharmaceutical manufacturers in contentious work regarding patent infringement claims, revocation actions and secondary use SPCs. Prior to his legal career he undertook a doctorate in medical microbiology. "A well-respected litigator." "Matthew Royle is clearly very clever and good at managing challenging situations."

Chambers and Partners UK 2023

Intellectual Property (patent litigation) - Band 3: Matthew Royle acts for pharmaceutical companies in patent litigation and also advises them on SPCs and regulation. He has taken a number of cases to the UK Supreme Court.

Chambers UK 2022

Life Sciences - IP/Patent Litigation: "A good litigator, with a good knowledge of the life sciences sector. He has a particular focus on the generics side."

Mehr

Intellectual Property - Patent Litigation

"The Impact Case of the Year" for Actavis v ICOS case, where we acted for Mylan in relation to litigation on two patents relating to Lilly's blockbuster drug Cialis® (tadalafil).

Leading individual - Life Sciences: IP/Patent (band 3) and IP: patent litigation (band 4).

Leading individual - Life Sciences: IP/Patent litigation (Band 3): Matthew Royle frequently represents pharmaceutical manufacturers in contentious work regarding patent infringement claims, revocation actions and secondary use SPCs. A source says: "He is a very good patent litigator – sensible, pragmatic and a pleasure to work with."

Leading individual - Intellectual Property: Patent litigation (Band 4): Matthew Royle acts for pharmaceuticals companies in patent litigation and also advises them on SPCs and regulation. A source says: "He is a very good patent litigator - sensible, pragmatic and a pleasure to work with."

Leading individual - TMT: Pharmaceuticals and Biotech

Leading individual: litigation (Bronze): Matthew Royle is a canny and highly trained harvester of SPC extensions – a “well-known, longstanding presence in intellectual property”.

Leading individual: Patents

Patent star

For Pregabalin Supreme Court case

Leading individual - Intellectual Property: Patent Litigation (Band 4): Matthew Royle is a patent litigator and pharmaceuticals regulation expert with an academic background in medical microbiology. A source says: "He is a real hands-on partner in a lot of major cases."

Leading individual - Life Sciences: IP/Patent Litigation (Band 3): Matthew Royle is known for representing generic pharmaceutical manufacturers in high-stakes patent litigation such as patent revocation actions and disputes concerning contested SPCs. A source says: "He is a real hands-on partner in a lot of major cases."

Leading individual - Intellectual Property: Patent Litigation (Band 4): Matthew Royle is a rising life sciences patent litigator whose recent work has involved questions of secondary medical uses, dosage regimes and SPCs. A market commentator says he is "very strong on the science."

Leading individual - Life Sciences: IP/Patent Litigation (Band 3): Matthew Royle is distinguished for his representation of generic pharmaceutical manufacturers in high-value patent revocation actions and cases concerning SPCs. Sources note that he is "very strong on the science."

‘Rising star’ in litigation

Experience

A life sciences company

A life sciences company on market formation dates in relation to orphan medicinal products.

Matthew Royle, Ph.D.

A life sciences company

A life sciences company on the validity of and expiry of supplementary protection certificates for a product launch.

Matthew Royle, Ph.D.

A life sciences company

A life sciences company on an EPO opposition in relation to a pharmaceutical.

Matthew Royle, Ph.D.

A company dealing with commercialisation arrangements for university discoveries

A company dealing with commercialisation arrangements for university discoveries on a dispute between co-inventors in relation to a patent.

Matthew Royle, Ph.D.

A life sciences company

A life sciences company on data exclusivity in relation to a combination product in the context of a sale of that product.

Matthew Royle, Ph.D.

News & Insights: Matthew Royle

Zu den Insights
Klicken Sie hier für Details
UPC

Pre-trial discovery before the UPC? – Pharmaceuticals, Trade fairs and beyond

19. Dezember 2025

von mehreren Autoren

Open podcast
Patent Perspectives Quick Listens

Episode 5: How is substantive law developing in the Unified Patent Court (UPC)?

In this episode Paul England is joined by Marie Keup, Matthew Royle and Verena Bertram.

17. März 2025

von mehreren Autoren

6 von 10 Podcasts

Klicken Sie hier für Details
Glass.Mapper.Sc.Fields.Image?.Alt
UPC

Good news for patent proprietors: the CoA's decision on the requirements for withdrawing an opt-out

25. November 2024
In-depth analysis

von mehreren Autoren

Klicken Sie hier für Details
Zu den Insights

Aktuelle News & Insights

Life Sciences & Healthcare

Forschung und Innovation als Standortfaktor – Rechtliche Weichenstellungen für Life Sciences made in Europe

27. Januar 2026
In-depth analysis

von Irina Rebin

Klicken Sie hier für Details
Life Sciences & Healthcare

Life Sciences made in Europe – Zur Life Sciences Strategie 2030 der Europäischen Kommission

27. Januar 2026

von Irina Rebin

Klicken Sie hier für Details
Disputes & Investigations

Key developments in AI disputes in 2025

23. Januar 2026
Briefing

von mehreren Autoren

Klicken Sie hier für Details
Life Sciences & Healthcare

Verabschiedung der EU-Durchführungsverordnung (EU) 2025/2086: Neue Regeln zur gemeinsamen klinischen Bewertung von Medizinprodukten und In-vitro-Diagnostika

23. Januar 2026

von Irina Rebin und Daniel Dietrich

Klicken Sie hier für Details
Logistik & Transport

EU Inc.: Gründer:innen und Unternehmen mit Expansionsplänen müssen jetzt strategisch denken

23. Januar 2026

von Dr. Benedikt Groh und Fritz Krings

Klicken Sie hier für Details
Life Sciences & Healthcare

Advising Nuclera on its extended Series C funding to US$87 million

22. Januar 2026

von Ross McNaughton und Oli Denne

Klicken Sie hier für Details
Life Sciences & Healthcare

Word on the street at the J.P. Morgan Healthcare Conference 2026: Part one

21. Januar 2026
In-depth analysis

von mehreren Autoren

Klicken Sie hier für Details
Life Sciences & Healthcare

Word on the street at the J.P. Morgan Healthcare Conference 2026: Part two

21. Januar 2026
In-depth analysis

von mehreren Autoren

Klicken Sie hier für Details
UPC

Territorial Scope of UPC Decisions under Article 34 UPCA: Recent Case Law, Interpretative Trends and Strategic Implications

15. Januar 2026
Briefing

von mehreren Autoren

Klicken Sie hier für Details
Life Sciences & Healthcare

Update aus Berlin: Bundesregierung verschärft Kurs in der Cannabispolitik

8. Januar 2026
Briefing

von Kathleen Munstermann-Senff, LL.M. (Medizinrecht) und Dr. Martin Jäger

Klicken Sie hier für Details
Mehr

Weitere Beraterinnen und Berater

UK
Simon Cohen

Simon Cohen

Partner

London
+44 20 7300 4815
E-Mail
Profil ansehen
Alle Beraterinnen und Berater

Meet me at

Alle Veranstaltungen und Webinare finden Sie auf unserer Event-Seite.

Alle Events
Newsletter-Anmeldung
  • Über Taylor Wessing
  • Campaigns and online tools
  • News
  • Unsere Anwälte
  • Expertise
  • International
  • Insights
  • Events
  • Presse & News
  • Kontakt
  • Karriere
  • Alumni
  • Datenschutzhinweise
  • Datenschutzbestimmungen & Cookie Hinweise
  • Rechtliche und regulatorische informationen
  • Regulatorische Informationen zu Kosten
  • Beschwerdeverfahren für Mandanten
  • Nutzungsbedingungen
  • Anti-slavery Statement
  • Nachhaltigkeit
  • Scam E-Mails

© Taylor Wessing